Immunostimulant In Situ Hydrogel Improves Synergetic Radioimmunotherapy of Malignant Glioblastoma Relapse Post‐Resection (Adv. Funct. Mater. 43/2022)

Abstract

Flexible Optoelectronics In article number 2205038, Huae Xu, Hongyi Liu, Jing Ji, Yun Chen, and co-workers present an injectable, reactive oxygen species-responsive therapeutic hydrogel (ADU-AAV-PD1@Gel), capable of sustained local release of soluble PD-1 (sPD-1) and STING agonist ADU-S100. The ADU-AAV-PD1@Gel combined with radiotherapy generates a robust antitumor immune response and induces long-term immune memory to prevent glioblastoma recurrence.